Startup profile · funding coverage
Boltz funding, valuation and investors
MIT-founded biotech applying open AI protein models to lab deployment (public-benefit corp).
Keep track of Boltz
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Seed
$28M · December 2025
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$28M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
seed · Cambridge, MA
Investors in latest funding
Lead: Zetta Venture Partners , Amplify Partners
Other: Andreessen Horowitz
Overview
Boltz is an MIT-associated biotechnology public-benefit corporation applying open AI protein structure models to laboratory deployment for drug discovery and biological research. In December 2025 the company raised a $28M seed round led by Zetta Venture Partners and Amplify Partners with Andreessen Horowitz participation, alongside Obvious Ventures and Factorial Capital. This Boltz is distinct from Boltz Exchange, the self-funded Bitcoin Lightning startup. The team focuses on bridging open-source protein AI (related to Boltz-1 model ecosystem) into practical wet-lab workflows.
Why Boltz is interesting
Large 2025 seed syndicate for MIT Boltz biotech — distinct from self-funded Bitcoin Lightning exchange Boltz Exchange; applies structural biology AI in lab settings.
Product & use cases
Deploys open AI protein modeling tools in biotech lab environments — connecting computational structure prediction to experimental validation pipelines.
- Protein structure prediction for drug target analysis
- Accelerating lab validation of AI-predicted structures
- Public-benefit research translation from open models
Key facts
- Seed (Dec 2025): $28M led by Zetta and Amplify; a16z participated
- MIT biotech PBC — not Bitcoin Boltz Exchange
- Co-investors: Obvious Ventures, Factorial Capital
Funding history (newest first)
Seed
2025-12 $28M- Zetta Venture Partners (lead)
- Amplify Partners (lead)
- Andreessen Horowitz (participant)
Investors in our directory
Funds linked from Boltz's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: MIT lineage and open-model ecosystem integration vs. closed proprietary structure platforms.
Protein AI moved from research novelty to funded biotech vertical in 2024–2025. Boltz competes on lab deployment of open models. Name collision with Bitcoin Boltz Exchange requires disambiguation in search.
-
Isomorphic Labs adjacent
DeepMind spinout for drug design with AI; larger scale.
-
Recursion adjacent
AI-driven drug discovery at industrial scale.
-
Boltz Exchange (Bitcoin) alternative
Unrelated Lightning Network company — same name, different sector.
-
Adaptyv adjacent
Named as a customer on Adaptyv’s Aug 25, 2026 $40M Series A post — wet-lab validation, not a Boltz round. See /startup/adaptyv.
Notable stories
- Large seed for MIT Boltz biotech drew press noting name confusion with Bitcoin Lightning Boltz.
- Public-benefit corp structure signals open-science alignment.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Boltz's financing or category context.
FAQs about Boltz
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.